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The aim of this study was to estimate the concentration of uric acid (UA) optically by using the original and processed ultraviolet
(UV) absorbance spectra of spent dialysate. Also, the eﬀect of using several wavelengths (multi-wavelength algorithms) for
estimation was examined. This paper gives an overview of seven studies carried out in Link¨ oping, Sweden, and Tallinn, Estonia.
A total of 60 patients were monitored over their 188 dialysis treatment procedures. Dialysate samples were taken and analysed by
means of UA concentration in a chemical laboratory and with a double-beam spectrophotometer. The measured UV absorbance
spectrawereprocessed.ThreemodelsfortheoriginalandthreefortheﬁrstderivateofUVabsorbancewerecreated;concentrations
of UA from the diﬀerent methods were ﬁnally compared in terms of mean values and SD. The mean concentration (micromol/L)
of UA was 49.7 ± 23.0 measured in the chemical laboratory, and 48.9 ± 22.4 calculated with the best estimate among all models.
The concentrations were not signiﬁcantly diﬀerent (P ≥ 0.17). It was found that using a multi-wavelength and processed signal
approach leads to more accurate results, and therefore these approaches should be used in future.
1.Introduction
Uric acid (UA), a ﬁnal product of the metabolism of purine,
is a very important biological molecule present in body
ﬂuids. It is mostly excreted from the human body through
the kidneys in the form of urine. The concentration of
UA in blood increases when the source of UA increases
or the kidneys malfunction. Hyperuricemia is a symptom
when the UA concentration is above 7mg/dL. UA is hard
to dissolve in blood and will crystallise when supersaturated.
The UA crystallites are deposited on the surface of the skin,
in joints, and particularly in the toes, resulting in gout.
Analysis of the UA concentration in blood helps to diagnose
gout. In addition to gout, hyperuricemia is connected with
lymph disorders, chronic haemolytic anaemia, an increase
in nucleic acid metabolism, and kidney malfunction. Ele-
vated serum UA contributes to endothelial dysfunction
and increased oxidative stress within the glomerulus and
tubulointerstitium, with associated increased remodelling
ﬁbrosis of the kidney [1]. A high level of serum UA,
hyperuricemia, has been suggested as an independent risk
factor for cardiovascular and renal diseases [2] especially in
patients with heart failure, hypertension, and/or diabetes [3–
5], and has been shown to cause renal disease in a rat model
[6]. UA is mostly associated with gout, but studies have
implied that UA aﬀects biological systems [7] and could also
inﬂuence the risk of higher mortality among dialysis patients
[8],althoughthepathogenicroleofhyperuricemiaindialysis
patientshasnotbeenfullyestablished[9].Highcaloricfoods
and alcohol as well as disorders of the organs and tissues
are the main causes of hyperuricaemia, obesity, kidney stone
formation, and even gout [10]. It is likely that high UA
levels in the blood are the reason for the emergence of
renal microvascular disease, which may be a key mechanism2 The Scientiﬁc World Journal
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Figure 1: Schematic clinical setup of the experiments.
in inducing salt-sensitive hypertension [11]. Harm can be
prevented and reduced by early diagnosis and monitoring,
especially by screening obese patients [12].
It would be advantageous to measure the concentration
of UA during dialysis online. For creating this opportunity
it is necessary to create accurate and reliable models. UA
may be the novel marker molecule for estimating the quality
of dialysis procedure, since the UA is uremic toxin itself,
removal pattern and amount of this compound during the
dialysis are informative for patients and medical personnel.
Ways of monitoring UA, dialysate, and other biological
ﬂuids with optical tools have been shown previously by
o u ra n do t h e rg r o u p s[ 13–15]. If you use a simple signal
processing tool for smoothing and calculating the ﬁrst
derivate of UV absorbance and/or absorbance or processed
absorbance values from several wavelengths, more reliable
results are achieved [16–20]. An eﬀective way of estimating
UA concentrations using the UV technique has been shown
in previous studies by our group. Current paper, involving
larger amount of patients from diﬀerent countries, presents
more general and accurate models making it possible to
apply the technique in the large patient community.
Theaimofthisstudywastoestimatetheconcentrationof
uric acid (UA) optically by using the original and processed
ultraviolet (UV) absorbance spectra of spent dialysate. Data
from diﬀerent dialysis centres and over a long period
was used to build models to increase general validity and
reliability.
2.MaterialsandMethods
All of the studies were performed after approval of the
protocol by the Regional Ethical Review Board, Link¨ oping,
Sweden,andbytheTallinnMedicalResearchEthicsCommit-
tee at the National Institute for Health Development, Esto-
nia. Informed consent was obtained from all participating
patients.
During the period 1999–2009 seven studies were carried
out in the Department of Dialysis and Nephrology at the
Link¨ oping University Hospital in Sweden and at the North
Estonian Medical Centre in Estonia. Clinical setup of the
experiments is presented in Figure 1. A summary of the
studies and information about the participating patients are
presented in Table 1.
The dialysers used in the studies, the eﬀective membrane
areas of the dialysers, the number of sessions when the
Table 1: Summary of the of the studies and patients participated.
Study No. of sessions No. of patients
(male/female) Mean age
1 40 10 (6/4) 63 ± 21
21 97 ( 4 / 3 ) 5 7 ± 23
3 40 10 (6/4) 60 ± 19
4 30 10 (7/3) 63 ± 19
51 17 ( 4 / 3 ) 5 6 ± 13
62 48 ( 7 / 1 ) 7 7 ± 7
72 48 ( 7 / 1 ) 7 7 ± 7
Table 2: Summary of the conditions of the studies.
Study Dialyser Area,
m2 N Dialysis machine
Blood
ﬂow,
mL/min
1 AF180 1.8 40 AK200 Fresenius
4008H 250–300
2 AF180 1.8 7 AK200
300–350 Polyﬂux17S 1.7 12 Fresenius 4008H
3
Polyﬂux17L 1.7 18 AK200
200–350
TCA150G 1.5 3 Fresenius 4008H
Nephral300 1.3 9
4
F8 1.8 14
Fresenius
4008H 245–350
F10 2.2 3
FX80 1.8 13
5 FX80 1.8 11 Fresenius 4008H 245–350
6 FX80 1.8 24 Fresenius 5008 280–350
7 FX800 1.8 24 Fresenius 5008 280–350
Table 3: Summary of the samples taken during the studies.
Study Sampling time, min.
1 5, 15, 30, 60, 90, 120, 180, 240, 270, 300, tank
2 5, 15, 30, 60, 90, 120, 180, 240, 255, 270, 300, tank
3 5, 60, 120, 180, 240, tank
4 10, 60, 120, 180, 240, tank
5 10, 60, 120, 180, 240
6 10, 240, tank
7 10, 30, 60, 120, 180, 240, 270, tank
respective dialyser was used, the type of dialysis machine
used, and blood ﬂow for the studies are presented in Table 2.
For all of the studies, samples of spent dialysate were
taken at discrete times for analysis (Table 3). The numbers
under“samplingtime”correspondtothenumberofminutes
after the start of hemodialysis. The dialysate samples were
taken at 255, 270, and 300 minutes when the duration of
sessions was long enough. Also, the sample from the total
dialysate collection tank was included in the analysis in most
cases.Puredialysatewascollectedbeforethestartofadialysis
session and used as the reference solution when the dialysis
machine was prepared and conductivity was stable.The Scientiﬁc World Journal 3
190 210 230 250 290 270 310 330 350 370
A
b
s
o
r
b
a
n
c
e
0 min
10 min
60 min
120 min
180 min
240 min
Tank
0
0.5
1
1.5
2
2.5
3
3.5
−0.5
Wavelength (nm)
(a)
190 210 230 250 290 270 310 330 350 370
0 min
10 min
60 min
120 min
180 min
240 min
Tank
−0.15
−0.1
−0.05
0
0.05
0.1
1
s
t
 
d
e
r
i
v
a
t
e
 
o
f
 
a
b
s
o
r
b
a
n
c
e
Wavelength (nm)
(b)
Figure 2: Example of absorbance spectrum (a) and ﬁrstderivate of absorbance spectrum (b)obtained over wavelength rangeof 190–380nm
on spent dialysate samples at diﬀerent times during dialysis session.
The concentration of UA was determined in the Clinical
Chemistry Laboratories at the North Estonian Medical Cen-
tre and at Link¨ oping University Hospital using standardised
methods.Theaccuracyofthemethods forthedetermination
of UA in dialysate was ±5%.
Double-beam spectrophotometers (UVIKON 943, Kon-
tron,Italy,andJASCOV-570,UV/VIS/NIRspectrophotome-
ter, Japan, in Link¨ oping and SHIMADZU UV-2401 PC,
Japan, in Tallinn) were used for the determination of UV
absorbance. Spectrophotometric analysis over a wavelength
range of 190–380nm was performed by an optical cell with
an optical path length of 1cm. A lower UV absorbance value
is obtained at all wavelengths versus time due to a decreased
concentration of UV-absorbing compounds in the blood
when transported through the dialyser into the dialysate and
removed from the blood during the dialysis treatment. The
treatments were also monitored with a single wavelength
online, and thereby all interruptions, self-tests, alarms, and
so forth could be identiﬁed directly on a screen. Some of
the measured values (absorbance or concentration) were
excluded from data before analysis. The exclusion criteria
were incorrect or illogical values of measured concentration
or absorption, for example, sampling coexisting with self-
tests of the dialysis machine.
The obtained UV spectra were processed with a
signal-processing tool using a Savitzky-Golay algorithm for
smoothing, and the ﬁrst derivative calculation wherein a
smoothing window with nine points was used (Figure 2).
Panorama Fluorescence 1.2 was used for signal processing,
and multiple stepwise regression analysis was performed
with Statistica 9.0. Final data processing was performed in
EXCEL (Microsoft Oﬃce Excel 2007).
On the basis of the UA concentrations measured in the
laboratory, measured UV absorbance spectra and processed
UV absorbance spectra, multiple regression analysis was
carried out on the calibration set of material (data from
75 randomly selected dialysis procedures). UA was set as
a dependent variable, and UV absorbance values between
190–380nm were set as independent variables. Multiple
linear regression (MLR) analysis using the forward stepwise
regression method was employed to determine the best
wavelengths for the models [21–25]. Using the stepwise
regression method helps us avoid mistakes in the models due
to the possible collinearity of the independent variables [26].
In both UV absorbance (UVa) and the ﬁrst derivate of UV
absorbance (UVd), the number of steps was increased until
no relevant improvements were achieved by means of model
performance. At each step the model for estimation of UA
was saved, resulting in diﬀerent models for both UVa and
UVd.
ModelsforthecalculationoftheconcentrationofUA(Y)
are in the form
Y = a+b1 ∗x1 +b2 ∗x2 + ···+bi ∗xi,( 1 )
where a is intercept, b is slope and x is an independent
variable (the value of original or derivate UV absorbance at a
certain wavelength).
The obtained models were used on the data from the
remaining 113 dialysis procedures (validation set) to calcu-
late the concentration of UA and compare these values with
the laboratory results and validate diﬀerent models.
Systematic error was calculated for the models as follows
[26]:
BIAS =
N
i=1ei
N
,( 2 )
where ei is the residual and N is the number of observations.
Standard error was calculated for the models as follows:
SE =
N
i=1(ei −BIAS)
2
N −1
. (3)4 The Scientiﬁc World Journal
Table 4: Summary of achieved models.
Model for a b1 ∗x1 b2 ∗x2 b3 ∗x3
original UV absorbance spectra at 294nm (UVa 1WL) −2.28 51.69∗A294
original UV absorbance spectra at 294 and 312nm (UVa 2WL) −1.67 60.56∗A294 −60.75∗A312
original UV absorbance spectra at 294, 312 and 266nm (UVa 3WL) −1.55 75.38∗A294 −62.27∗A312 –7.36∗A266
derivative spectra at 300nm (UVd 1WL) −1.44 −1038.84∗D300
derivative spectra at 300 and 270nm (UVd 2WL) −2.12 −1111.09∗D300 128.67∗D270
derivative spectra at 300, 270 and 222nm (UVd 3WL) −3.56 −1128.73∗D300 120.74∗D270 −32.54∗D222
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Figure 3: Behavior of RMSE with diﬀerent models including 1–4
independent variables.
Root mean squared error was calculated for the models as
follows:
RMSE =
N
i=1(ei)
2
N
. (4)
3. Results
During regression analysis, three steps were considered
suﬃcient after estimation of the behaviour of the root mean
squared error (RMSE). From Figure 3 it was concluded
that adding one additional wavelength to the models did
not markedly improve the results in terms of RMSE. This
was also conﬁrmed by a t-test for residuals, which were
signiﬁcantly diﬀerent (at P level 0.05) between models that
usedanabsorbanceorﬁrstderivateofabsorbancevaluefrom
one, two, or three wavelengths and which were not diﬀerent
in the case of models which used four wavelengths.
As a result of regression analysis, three models for UV
absorbance and three models for derivate of UV absorbance
were found wherein each used an absorption or derivate
of absorption value from one, two, or three wavelengths,
respectively (Table 4) .T h em o d e l sw e r em a r k e da sU V a1WL
for the model which used a UV absorbance value from one
wavelength, UVa 2WL for the same information from two
wavelengths,andsoon.UVd 1WL-UVd 3WLmarksmodels
which used a derivative value of UV absorbance from one,
two, or three wavelengths.
Figures 4 and 5 show the wavelengths of original UV
absorbance and ﬁrst derivate of UV absorbance included in
the models for estimating UA concentration.
The models presented in Figures 4 and 5 were applied
to the material to calculate UA concentrations, R2, BIAS, SE,
and RMSE. The results are presented in Table 5.
The concentrations achieved by the models were not
signiﬁcantly diﬀerent (P = 0.17–0.48) from the observed
concentrations in the laboratory for any model.
The systematic and root mean squared errors were
signiﬁcantly diﬀerent (at P level 0.05) in the following cases
(validation group):
(a) UVa 1WL versus UVd 1WL,
(b) UVa 1WL versus UVa 2WL,
(c) UVa 1WL versus UVa 3WL,
(d) UVd 1WL versus UVd 3WL,
(e) UVd 2WL versus UVd 3WL.
The diﬀerences between individual values of the UA
concentration from the laboratory and UA values from two
models(UVa 3WLandUVd 3WL)arepresentedinFigure 6.
The root mean squared error decreased as wavelengths
were added to the models in the case of both the UVa and
UVd models, and the decrease was slightly greater in the case
of UVd models.
These results demonstrate that using UV absorbance
from several wavelengths provides more accurate results
in the estimation of the concentration of UA. Also, using
information from the ﬁrst derivate of spectra instead of
original UV absorbance spectra produces a notable eﬀect.
4. Discussion
The results in Table 5 show that it is possible to estimate UA
concentration in spent dialysate using UV absorbance data.
The presented models were built on the calibration set of
material which contained absorbance values from Tallinn,
Estonia, and Link¨ oping, Sweden. The data included in the
study were collected during seven studies from 1999 to 2009.The Scientiﬁc World Journal 5
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Figure 4: Models using UV absorbance values from one, two, or three wavelengths to estimate concentration of UA: (a) calibration group
(N = 579) and (b) validation group (N = 639).
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calibration group (N = 579) and (b) validation group (N = 639).6 The Scientiﬁc World Journal
Table 5: Summary of results of diﬀerent methods of measuring concentration of uric acid.
Method Set N Concentration of UA ± SD
(micromol/L) R2 BIAS SE RMSE
Lab Cal. 579 52.1 ± 23.3 — — — —
Val. 639 49.7 ± 23.0 — — — —
UVa 1WL Cal. 579 52.1 ± 22.3 0.91 0.00 6.83 6.83
Val. 639 48.9 ± 21.8 0.86 −0.88 8.70a,b,c 8.74a,b,c
UVa 2WL Cal. 579 52.1 ± 22.5 0.93 0.00 6.19 6.19
Val. 639 48.1 ± 21.6 0.88 −1.70 8.00 8.18
UVa 3WL Cal. 579 52.1 ± 22.6 0.94 0.00 5.52 5.52
Val. 639 48.4 ± 21.8 0.92 −1.39 6.39 6.54
UVd 1WL Cal. 579 52.1 ± 22.6 0.94 0.00 5.64 5.64
Val. 639 48.2 ± 21.8 0.91 −1.57 7.05d 7.22d
UVd 2WL Cal. 579 52.1 ± 22.8 0.95 0.00 4.95 4.95
Val. 639 48.7 ± 22.3 0.93 −1.07 5.94e 6.04e
UVd 3WL Cal. 579 52.1 ± 22.8 0.96 0.00 4.83 4.83
Val. 639 48.9 ± 22.4 0.93 −0.89 5.92 5.99
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Figure 6: The Bland-Altman plots. (a) The diﬀerence between UA Lab and UVa 3WL is plotted against the mean value of UA Lab and
UVa 3WL (N = 639). (b) The diﬀerence between UA Lab and UVd 3WL is plotted against the mean value of UA Lab and UVd 3WL
(N = 639).
The coeﬃcient of determination, R2, between the
laboratory and calculated values of UA are higher or
equal in the case of the UVd (single/two/three) com-
pared to the UVa (single/two/three) (0.86/0.88/0.92 versus
0.91/0.93/0.93) (Figures 4 and 5). Also, the systematic error
and RMSE are lower if we use several wavelengths and/or
derivate spectra (Table 5). This indicates that using several
wavelengths instead of a single one produces a signiﬁcant
eﬀect, which is larger when we use processed spectra instead
oforiginalabsorbancespectra.However,itseemsthatadding
a third wavelength to the UVd model does not improve
results in terms of R2, although the results of systematic
error and RMSE improve. For describing the diﬀerences
between individual values of the UA concentration from the
laboratory and UA values from models, a Bland Altman
plot for two models (UVa 3WL and UVd 3WL) was created
(Figure 6); diﬀe r e n c e si nU Av a l u e sw e r es o m e w h a ts m a l l e r
in the case of the model using derivate spectral values.
Considering the improvement in the accuracy of the
model,systematicerrorandRMSE,thesignalprocessingand
information from several wavelengths should be used in the
future. In this study the best result was achieved with the
model using derivate spectra values at three wavelengths.
It was found that haemodialysis adequacy can be quan-
tiﬁed using UV absorbance of spent dialysate. By using this
method,itispossibletoreducecostsbyreducingthenumber
of blood samples and amount of laboratory analyses [27].
A good way of estimating UA concentrations using the
UV technique has been shown in previous studies [13, 14,
16–20], but if we use signal processing tools and absorbance
information from several wavelengths, we can essentially
improve the accuracy and reliability of the results.
A previous study by our group [28] indicated that
app. 90% of the cumulative and integrated UV absorbance
measured by the optical dialysis adequacy sensor originates
from the ten main peaks of a particular dialysis treatment,The Scientiﬁc World Journal 7
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Figure 7: Average values of measured UV absorbance for total
material and contribution of UA to UV absorbance.
one of which is UA. Another study where HPLC analysis
was used indicated that the main solute responsible for UV
absorbance of around 280nm is UA [29].
A sc a nb es e e nf r o mFigure 7, the contribution of UA
to total UV absorbance (UV (UA)/UV average presents an
average absorbance sourced from UA in the dialysate divided
byaverageUVabsorbanceofthewholedialysate)isrelatively
large in the wavelength region of 280–310nm. This explains
the wavelengths appearing in the models. UA absorbance
spectra have one minimum around 265, and this explains
why the wavelength is also included in the models.
The high correlation between UV absorbance and UA
could be explained by the characteristic absorbance around
294nm for UA in combination with the relatively high
molar extinction coeﬃcients of UA in this wavelength
region compared to other chromophores among uremic
retention solutes eliminated from blood into spent dialysate
during dialysis [30]. This makes it possible to determine
UA concentration even when the technique does not solely
measure UA.
TheuseofaSavitzky-Golayalgorithmforsmoothingand
ﬁrst derivate calculation is an eﬀective method of correcting
baseline eﬀects in spectra, which could explain the improve-
ment in accuracy. Using UV absorbance and processed UV
absorbance information from several wavelengths reduces
randomness and is probably the reason why better results
have been achieved.
In this study, multiple linear regression (MLR) analysis
using the forward stepwise regression method was used
to determine the best wavelengths for models. Using the
stepwise regression method helps us to avoid mistakes in the
models due to the possible collinearity of independent vari-
ables. It seems that models developed with MLR are relevant
and work well in a validation set of material, although using
otherapproacheslikepartialleastsquaresregression(PLS-R)
or principal component regression (PCR) to create models
should be considered in the future [26].
The clinical aim in the future is to develop an online
monitoring system that oﬀers an estimation of the removal
of clinically important solute and marker UA during
haemodialysis.
Also, regarding the optical properties of UA, it is
possible to develop an optical system to measure the UA
concentration in blood and/or urine. This makes it possible
to rapidly detect hyperuricemia widely and at an early stage.
This is very important in preventing serious clinical issues
caused by hyperuricemia [2–6, 8, 11, 12, 31].
An accurate optical method makes it possible to measure
UA rapidly online without the need for blood samples and
disposables or chemicals. Using a simple signal-processing
tool and UV absorbance values from several wavelengths
could be very helpful in achieving more accurate and reliable
results.
5. Conclusion
Thisstudyinvestigatedtheeﬀectofusingseveralwavelengths
and a simple signal processing to estimate the concentration
ofUAindialysateusinganopticalmethod.Thedataanalysed
were collected over 10 years: 60 patients participated and 188
dialysis sessions were monitored in various centres in dif-
ferent countries. It was found that using a multi-wavelength
andprocessedsignalapproachleadstomoreaccurateresults.
This approach enables us to develop an advantageous,
reliable, and cost-eﬀective method of measuring the concen-
tration of UA, an independent risk marker of cardiovascular
and renal diseases and also a novel risk factor for type 2
diabetes mellitus. Developed algorithms could be used in
optical dialysis quality monitors; these monitors should be
integratedtodialysismachinesandwiththeseseveralparam-
eters; UA among them is possible to monitor during the
dialysis. No blood will be monitored; removal on substances
ispossibletoestimateonlybymonitoringthespentdialysate.
A future method evaluates the treatment dose and makes it
possible to control treatments against set target values.
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